Literature DB >> 11869658

Condom effectiveness in reducing heterosexual HIV transmission.

S Weller1, K Davis.   

Abstract

BACKGROUND: The amount of protection that condoms provide for HIV and other sexually transmitted infections is unknown. Cohort studies of sexually active HIV serodiscordant couples with follow-up of the seronegative partner, provide a situation in which a seronegative partner has known exposure to the disease and disease incidence can be estimated. When some individuals use condoms and some do not, namely some individuals use condoms 100% of the time and some never use (0%) condoms, condom effectiveness can be estimated by comparing the two incidence rates. Condom effectiveness is the proportionate reduction in disease due to the use of condoms.
OBJECTIVES: The objective of this review is to estimate condom effectiveness in reducing heterosexual transmission of HIV. SEARCH STRATEGY: Studies were located using electronic databases (AIDSLINE, CINAHL, Embase, and MEDLINE) and handsearched reference lists. SELECTION CRITERIA: For inclusion, studies had to have: (1) data concerning sexually active HIV serodiscordant heterosexual couples, (2) a longitudinal study design, (3) HIV status determined by serology, and (4) contain condom usage information on a cohort of always (100%) or never (0%) condom users. DATA COLLECTION AND ANALYSIS: Studies identified through the above search strategy that met the inclusion criteria were reviewed for inclusion in the analysis. Sample sizes, number of seroconversions, and the person-years of disease-free exposure time were recorded for each cohort. If available, the direction of transmission in the cohort (male-to-female, female-to-male), date of study enrollment, source of infection in the index case, and the presence of other STDs was recorded. Duplicate reports on the same cohort and studies with incomplete or nonsepecific information were excluded. HIV incidence was estimated from the cohorts of "always" users and for the cohorts of "never" users. Effectiveness was estimated from these two incidence estimates. MAIN
RESULTS: Of the 4709 references that were initially identified, 14 were included in the final analysis. There were 13 cohorts of "always" users that yielded an homogeneous HIV incidence estimate of 1.14 [95% C.I.:.56, 2.04] per 100 person-years. There were 10 cohorts of "never" users that appeared to be heterogeneous. The studies with the longest follow-up time, consisting mainly of studies of partners of hemophiliac and transfusion patients, yielded an HIV incidence estimate of 5.75 [95% C.I.: 3.16, 9.66] per 100 person-years. Overall effectiveness, the proportionate reduction in HIV seroconversion with condom use, is approximately 80%. REVIEWER'S
CONCLUSIONS: This review indicates that consistent use of condoms results in 80% reduction in HIV incidence. Consistent use is defined as using a condom for all acts of penetrative vaginal intercourse. Because the studies used in this review did not report on the "correctness" of use, namely whether condoms were used correctly and perfectly for each and every act of intercourse, effectiveness and not efficacy is estimated. Also, this estimate refers in general to the male condom and not specifically to the latex condom, since studies also tended not to specify the type of condom that was used. Thus, condom effectiveness is similar to, although lower than, that for contraception.

Entities:  

Mesh:

Year:  2002        PMID: 11869658     DOI: 10.1002/14651858.CD003255

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  222 in total

Review 1.  HIV/AIDS prevention in Latino and African-American communities.

Authors:  Claudia Medina; William Johnson
Journal:  J Natl Med Assoc       Date:  2004-02       Impact factor: 1.798

2.  HIV/AIDS therapy and prevention: The two solitudes.

Authors:  Jocelyne Piret; Michel G Bergeron
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

3.  "I can't use a condom, I am a Christian:" salvation, death, and… naivety in Africa.

Authors:  Adamson S Muula
Journal:  Croat Med J       Date:  2010-10       Impact factor: 1.351

Review 4.  Interventions to reduce sexual risk for human immunodeficiency virus in adolescents: a meta-analysis of trials, 1985-2008.

Authors:  Blair T Johnson; Lori A J Scott-Sheldon; Tania B Huedo-Medina; Michael P Carey
Journal:  Arch Pediatr Adolesc Med       Date:  2011-01

5.  Plax Responds.

Authors:  Kathryn Plax
Journal:  Am J Public Health       Date:  2015-09-17       Impact factor: 9.308

6.  Prevalence and predictors of facing a legal obligation to disclose HIV serostatus to sexual partners among people living with HIV who inject drugs in a Canadian setting:a cross-sectional analysis.

Authors:  Sophie Patterson; Angela Kaida; Paul Nguyen; Sabina Dobrer; Gina Ogilvie; Robert Hogg; Thomas Kerr; Julio Montaner; Evan Wood; M-J Milloy
Journal:  CMAJ Open       Date:  2016-04-28

7.  Receipt and use of free condoms among US men who have sex with men.

Authors:  Christine Khosropour; Patrick S Sullivan
Journal:  Public Health Rep       Date:  2013 Sep-Oct       Impact factor: 2.792

Review 8.  Antiretrovirals and safer conception for HIV-serodiscordant couples.

Authors:  Lynn T Matthews; Jennifer A Smit; Susan Cu-Uvin; Deborah Cohan
Journal:  Curr Opin HIV AIDS       Date:  2012-11       Impact factor: 4.283

9.  Higher contraceptive uptake in HIV treatment centers offering integrated family planning services: A national survey in Kenya.

Authors:  Yilin Chen; Emily Begnel; Wangui Muthigani; Dunstan Achwoka; Christine J Mcgrath; Benson Singa; Joel Gondi; Lucy Ng'ang'a; Agnes Langat; Grace John-Stewart; John Kinuthia; Alison L Drake
Journal:  Contraception       Date:  2020-04-13       Impact factor: 3.375

Review 10.  Combination implementation for HIV prevention: moving from clinical trial evidence to population-level effects.

Authors:  Larry W Chang; David Serwadda; Thomas C Quinn; Maria J Wawer; Ronald H Gray; Steven J Reynolds
Journal:  Lancet Infect Dis       Date:  2013-01       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.